1. Volume 95, Issue 4, Pages 983-991 (April 2019)
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients 
Fabian Hammer, Uwe Malzahn, Julian Donhauser, Christoph Betz, Markus P. Schneider, Clemens Grupp, Nils Pollak, Stefan Störk, Christoph Wanner, Vera Krane Susanne Berweck, Patrick Biggar, Christoph Blaser, Thomas Bochannek, Frank Breunig, Michael Brunner, Beatrix Büschges-Seraphin, Stefan Büttner, Ahmet Cakmak, Thomas Döltz, Mara Dörken, Kai-Uwe Eckardt, Heribert Fink, Stefan Fischer, Wolfgang Freisinger, Tilo Freiwald, Julian Gebhardt, Helmut Geiger, Rüdiger Götz, Jan Goßmann, Renate Hammerstingl, Joanna Harazny, Michael Heckel, Andrea Heyd-Schramm, Joachim Hoyer, Rolf Janka, Oliver Jung, Markus Ketteler, Christina Klaeffling, Claudius Kleinert, Marianne Kleinert, Arnfried Klingbeil, Thorsten Klink, Benjamin-Florian Koch, Judith Kosowski, Michael Leidig, Jens Lutz, Mohamed Marwan, Maria Moritz, Brigitte Moye, Holger Naujoks, Kai-Olaf Netzer, Ulrike Raff, Clemens Reichert, Imke Reimer, Jurij Ribel, Sophie Richter, Christian Ritter, Sarah Rudolf, Beate Schamberger, Michael Schmid, Thomas Schmiedeke, Andreas Schmitt, Heike Schneider, Reinhard Schneider, Cord Schneuzer, Markus Schöffauer, Lothar Schramm, Sabine Schütterle, Susanne Schwedler, Ewelina Sobkowiak, Daniel Sollinger, Frank Strutz, Sebastian Toncar, Vladimir Vasiljuk, Thomas Vogl, Thorsten Walther, Julia Weinmann-Menke, Bettina Wirth, Hendrick Witsch, Paul Würmell, Raoul Zeltner, Josef Zimmermann Fabian Hammer, Uwe Malzahn, Julian Donhauser, Christoph Betz, Markus P. Schneider, Clemens Grupp, Nils Pollak, Stefan Störk, Christoph Wanner, Vera Krane Susanne Berweck, Patrick Biggar, Christoph Blaser, Thomas Bochannek, Frank Breunig, Michael Brunner, Beatrix Büschges-Seraphin, Stefan Büttner, Ahmet Cakmak, Thomas Döltz, Mara Dörken, Kai-Uwe Eckardt, Heribert Fink, Stefan Fischer, Wolfgang Freisinger, Tilo Freiwald, Julian Gebhardt, Helmut Geiger, Rüdiger Götz, Jan Goßmann, Renate Hammerstingl, Joanna Harazny, Michael Heckel, Andrea Heyd-Schramm, Joachim Hoyer, Rolf Janka, Oliver Jung, Markus Ketteler, Christina Klaeffling, Claudius Kleinert, Marianne Kleinert, Arnfried Klingbeil, Thorsten Klink, Benjamin-Florian Koch, Judith Kosowski, Michael Leidig, Jens Lutz, Mohamed Marwan, Maria Moritz, Brigitte Moye, Holger Naujoks, Kai-Olaf Netzer, Ulrike Raff, Clemens Reichert, Imke Reimer, Jurij Ribel, Sophie Richter, Christian Ritter, Sarah Rudolf, Beate Schamberger, Michael Schmid, Thomas Schmiedeke, Andreas Schmitt, Heike Schneider, Reinhard Schneider, Cord Schneuzer, Markus Schöffauer, Lothar Schramm, Sabine Schütterle, Susanne Schwedler, Ewelina Sobkowiak, Daniel Sollinger, Frank Strutz, Sebastian Toncar, Vladimir Vasiljuk, Thomas Vogl, Thorsten Walther, Julia Weinmann-Menke, Bettina Wirth, Hendrick Witsch, Paul Würmell, Raoul Zeltner, Josef Zimmermann 
Kidney International 
Volume 95, Issue 4, Pages (April 2019)
DOI: /j.kint
Copyright © 2019 International Society of Nephrology Terms and Conditions

2. Kidney International 2019 95, 983-991DOI: (10.1016/j.kint.2018.11.025)
Copyright © 2019 International Society of Nephrology Terms and Conditions

3. Figure 1
CONSORT trial flow diagram. Dropouts postrandomization were defined as patients without 2 analyzable CMR scans. CMR, cardiac magnetic resonance; MRI, magnetic resonance imaging.
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions

4. Figure 2
(a) Change in left ventricular mass index (LVMi) after 40 weeks of treatment with spironolactone or placebo. (b) Mean change in LVMi according to LVMi at baseline by treatment allocation (spironolactone vs. placebo).
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions

5. Figure 3
Change in mean 24-hour systolic (a) and diastolic (b) ambulatory blood pressure (ABP) in spironolactone- and placebo-treated patients.
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions

6. Figure 4
Mean predialysis potassium levels in the spironolactone and placebo groups during the entire study period. FUP, follow-up; PRI, placebo run-in phase.
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions